Cooley Advises Synthorx on $2.5 Billion Sanofi Purchase
It’s another premium life sciences M&A mandate for the Palo Alto-headquartered firm.
In what is likely to be Cooley’s final major transaction of the year, it advised biotech company Synthorx on its sale to French pharmaceuticals giant Sanofi for $2.5 billion – giving the latter an oncology boost.
Synthorx, which focuses on prolonging and improving the lives of cancer sufferers and those with auto-immune diseases, is noted for its expanded genetic alphabet platform technology, which broadens the genetic code by adding a new DNA base pair. It will augment and complement Sanofi’s existing gene-related platforms.
“Synthorx’s exceptionally novel discovery platform has already produced a molecule that has the potential to become a foundation of the next generation of immuno-oncology combination therapies,” explained Sanofi’s global head of R&D, Dr. John Reed. “By selectively expanding the numbers of effector T-cells and natural killer cells in the body, THOR-707 can be combined with our current oncology medicines and our emerging pipeline of immuno-modulatory agents for treating cancer.
“Moreover, Synthorx’s pipeline of engineered lymphokines has great promise not only for oncology but also for addressing many autoimmune and inflammatory diseases.”
Barbara Borden, Rama Padmanabhan and Ken Rollins were the Cooley partners leading the deal for Synthorx.
In the last five years, Cooley has acted on over a thousand M&A deals, with an aggregate value of around $400 billion. Its other major life sciences deals this year include advising BioTime on its purchase of Asterias Biotherapeutics (a matter led by partner Tali Sealman), and acting for Therachon, a biotech company focusing on rare diseases, on its $810 million sale to Pfizer (led by partners Ryan Sansom and Michal Berkner).
Legal advisor to Sanofi: Weil, Gotshal & Manges
Financial advisor to Sanofi: Morgan Stanley
Legal advisor to Synthorx: Cooley
Financial advisor to Synthorx: Centerview Partners
The European Commission’s approval of the copyright directive in April threw more gas on the fire. In a few years, the internet has become – among other things – the main market fo
The long-serving boss of Cobepa, Jean-Marie Laurent Josi talks about the business model of a Belgian investment firm that is trusted by major European families, one which marries t
Since the last half of 2008, it is no longer possible to conceal the term ‘crisis’. New paradigms have become apparent and structural changes are predicted. Indeed mar